tbuckley/cabot-search huggingface dataset:
Redox responsive nanoparticle encapsulating black phosphorus quantum dots for cancer theranostics
Authors: Haolin Chen, Zhiming Liu, Bo Wei, Jun Huang, Xinru You, Jingyang Zhang, Zhiling Yuan, Zhilie Tang, Zhouyi Guo, Jun Wu
Journal: Bioactive Materials (2020)

Effective cancer treatment puts high demands for cancer theranostics. For cancer diagnostics, optical coherence tomography (OCT) technology (including photothermal optical coherence tomography (PT-OCT)) has been widely investigated since it induces changes in optical phase transitions in tissue through environmental changes (such as temperature change for PT-OCT). In this report, redox responsive nanoparticle encapsulating black phosphorus quantum dots was developed as a robust PT-OCT agent. Briefly, black phosphorus quantum dots (BPQDs) are incorporated into cysteine-based poly-(disulfide amide) (Cys-PDSA) to form stable and biodegradable nanoagent. The excellent photothermal feature allows BPQD/Cys-PDSA nanoparticles (NPs) as a novel contrast agent for high-resolution PT-OCT bioimaging. The Cys-PDSA can rapidly respond to glutathione and effectively release BPQDs and drugs in vitro and in vivo. And the obtained NPs exhibit excellent near-infrared (NIR) photothermal transduction efficiency and drug delivery capacity that can serve as novel therapeutic platform, with very low chemo drug dosage and side effects. Both of the polymer and BPQD are degradable, indicating this platform is a rare PT-OCT agent that is completely biodegradable. Overall, our research highlights a biodegradable and biocompatible black phosphorus-based nanoagent for both cancer diagnosis and therapy.
233P Sexual dysfunction among premenopausal breast cancer survivors
Authors: F. Pontes, R. Basto, C.I. de Sousa Amorim Sampaio da Costa, A.R. Monteiro, F.R. Salgueiro, J.C. Magalhaes, M.J.P. de Sousa, F. Macedo, R. Félix Soares, T. Cunha Pereira, I. Domingues, S.C. Póvoa, A.R. Garcia, S. Broco, P. Madeira, A. Pego, T.M. Pereira de Carvalho Tavares, M.I. Pazos Portela, M. Mariano, G. Sousa
Journal: Annals of Oncology (2020)
1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone
Authors: C. Robert, G.V. Long, J. Larkin, J.D. Wolchok, J.C. Hassel, D. Schadendorf, F.S. Hodi, C. Lebbé, J-J. Grob, K. Grossmann, J. Wagstaff, J. Chesney, M.O. Butler, O. Bechter, I. Márquez-Rodas, A.C. Pavlick, S. Re, W. van Dijck, M.A. Postow, P.A. Ascierto
Journal: Annals of Oncology (2020)
165MO Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study
Authors: J. O'Shaughnessy, S. Sousa, J. Cruz, L. Fallowfield, P. Auvinen, C. Pulido, A. Cvetanovic, S. Wilks, L. Ribeiro, M. Burotto, D. Klingbiel, D. Messeri, A. Alexandrou, P. Trask, J. Fredriksson, Z. Machackova, L. Stamatovic
Journal: Annals of Oncology (2020)
1164P Prognostic value of miRNA profiling in neuroendocrine neoplasias (NENs) from lung and gastroenteropancreatic (GEP) origin
Authors: P. Espinosa-Olarte, B. Soldevilla, C. Carretero-Puche, S. Molina-Pinelo, C. Robles, M. Benavent, L. Gomez-Izquierdo, P. Morales-Burgo, P. Jimenez-Fonseca, M. Fierro-Fernandez, A. La Salvia, A. Lens-Pardo, M.C. Riesco-Martinez, R. Garcia-Carbonero
Journal: Annals of Oncology (2020)
1289P Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
Authors: A. Drilon, V. Moreno, J. Patel, U.N. Lassen, B. Solomon, L. Rosen, S. Leyvraz, D.S.W. Tan, J.A. Reeves, L. Dima, N. Brega, S. Kummar, A.F. Farago
Journal: Annals of Oncology (2020)
667P Impact of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) on overall survival (OS) in patients (p) with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel (D) plus androgen-deprivation therapy (ADT)
Authors: L. Notario, J.M. Piulats, N. Sala, U. Ferrandiz, A. González, O. Etxániz, L. Heras, O. Buisan, L. Del Carpio, A. Álvarez, A. Boladeras, A. Roselló, P. Barretina, C. Fina, J.C. Pardo, J.M. Suárez, J. Comet, X. Garcia del Muro, A. Esteve, A. Font
Journal: Annals of Oncology (2020)
1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
Authors: J. Niu, A. Nagrial, M. Voskoboynik, H.C. Chung, D.H. Lee, M-J. Ahn, T.M. Bauer, A. Jimeno, V. Chung, K.F. Mileham, E. Chartash, D. Chen, J. Healy, M. Rajasagi, C. Maurice-Dror
Journal: Annals of Oncology (2020)
LBA76_PR Expected medium and long term impact of the COVID-19 outbreak in oncology
Authors: G. Jerusalem, C.E. Onesti, D.G. Generali, N. Harbeck, H. Wildiers, G. Curigliano, M. Campone, V. Tjan-Heijnen, M. Martin, M. Cristofanilli, L. Pusztai, R. Bartsch, M. Peeters, G. Berchem, M. Tagliamento, J. Cortés, T. Ruhstaller, E.M. Ciruelos, S. Rottey, H.S. Rugo
Journal: Annals of Oncology (2020)
920P Avelumab (anti-PD-L1) in patients with platinum-refractory/ineligible recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Results from a phase Ib cohort
Authors: J. Guigay, K-W. Lee, M.R. Patel, A. Daste, D.J. Wong, S. Goel, M. Gordon, M. Gutierrez, A. Balmanoukian, C. Le Tourneau, A. Mita, D. Vansteene, U. Keilholz, P. Schöffski, H.J. Grote, D. Zhou, M. Bajars, N. Penel
Journal: Annals of Oncology (2020)
593P Longitudinal description of clinical trials for the development of cyclin-dependent kinases inhibitors
Authors: C. Cardone, C. Schettino, P. Gargiulo, L. Arenare, S. Bevilacqua, G. Buonfanti, A. del Giudice, A. Gimigliano, M.T. Ribecco, A. Gravina, F. Perrone, M.C. Piccirillo
Journal: Annals of Oncology (2020)
1951P Niraparib and irinotecan combination in ATM-mutated colorectal cancer
Authors: P.P. Vitiello, G. Martini, L. Mele, E.F. Giunta, V. De Falco, D. Ciardiello, V. Belli, C. Cardone, N. Matrone, L. Poliero, V. Tirino, F. Selvaggi, G. Papaccio, T. Troiani, V. Desiderio, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2020)
1736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer
Authors: K. Ramkumar, C.A. Stewart, C. Gay, R. Cardnell, L. Diao, Q. Wang, L. Shen, Y. Xi, S. Kundu, C. Della Corte, D. Gibbons, J. Wang, J.V. Heymach, L.A. Byers
Journal: Annals of Oncology (2020)
880TiP Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC study
Authors: A. Oaknin, M. Iglesias, J.D. Alarcon, G. Villacampa Javierre, L. Gaba Garcia, A. Santaballa, L.M. Manso, I. Romero, M.P. Barretina Ginesta, C. Churruca, Y. García, A.B. Sanchez, G. Marquina, B. Pardo, A. Redondo, M.J. Rubio, A. González Martín
Journal: Annals of Oncology (2020)
Policy Progress in Reducing Sodium in the American Diet, 2010–2019
Authors: Aviva A. Musicus, Vivica I. Kraak, Sara N. Bleich
Journal: Annual Review of Nutrition (2020)

Most Americans consume dietary sodium exceeding age-specific government-recommended targets of 1,500–2,300 mg/day per person. The majority (71%) of US dietary sodium comes from restaurant and packaged foods. Excess sodium intake contributes to hypertension and cardiovascular disease, which is the leading cause of death in the United States. This review summarizes evidence for policy progress to reduce sodium in the US food supply and the American diet. We provide a historical overview of US sodium-reduction policy (1969–2010), then examine progress toward implementing the 2010 National Academy of Medicine (NAM) sodium report's recommendations (2010–2019). Results suggest that the US Food and Drug Administration made no progress in setting mandatory sodium-reduction standards, industry made some progress in meeting voluntary targets, and other stakeholders made some progress on sodium-reduction actions. Insights from countries that have significantly reduced population sodium intake offer strategies to accelerate US progress toward implementing the NAM sodium-reduction recommendations in the future.
Association of Pregnancy With Recurrence of Spontaneous Coronary Artery Dissection Among Women With Prior Coronary Artery Dissection
Authors: Marysia S. Tweet, Kathleen A. Young, Patricia J. M. Best, Meredith Hyun, Rajiv Gulati, Carl H. Rose, Sharonne N. Hayes
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Spontaneous coronary artery dissection (SCAD) is a notable cause of acute coronary syndrome in women of childbearing age. <h3>Objective</h3> To test the hypothesis that pregnancy after SCAD is associated with recurrent SCAD. <h3>Design, Setting, and Participants</h3> Three study designs were implemented: a case series of women with pregnancy after SCAD; a nested case-control study comparing patients with recurrent SCAD to matched controls without recurrent SCAD; and a cohort study. Women with SCAD who were of childbearing potential and enrolled into the Mayo Clinic SCAD Registry from August 30, 2011, to April 4, 2019, were included in the study. Patients with coronary dissections associated with iatrogenesis, trauma, or atherosclerosis were not enrolled. <h3>Exposures</h3> Pregnancy after SCAD. <h3>Main Outcomes and Measures</h3> The primary outcome was SCAD recurrence, defined as an acute coronary syndrome or cardiac arrest due to new SCAD. Other demographic measures collected included age, year of SCAD occurrence, and comorbidities. <h3>Results</h3> The cohort included 636 women of childbearing potential. Twenty-three of those women had a total of 32 pregnancies after SCAD. The median (interquartile range) age of women with pregnancy after SCAD was 38 years (34-40 years), and 20 (87%) were White. In the nested case-control study, 92 cases of recurrent SCAD were matched to 158 controls. There was no significant difference in exposure to subsequent pregnancies in the women with recurrent SCAD as compared with matched controls (2 of 92 [2%] vs 13 of 158 [8%];<i>P</i> = .06). In the overall cohort of 636 patients, recurrent SCAD was present in 122 patients with a Kaplan-Meier 5-year SCAD recurrence estimate of 14.8%. The Cox analysis showed no significant association between subsequent pregnancy and SCAD recurrence with a nonsignificant hazard ratio of 0.38 (95% CI, 0.09-1.6) when controlling for age at first SCAD, year of first SCAD, and fibromuscular dysplasia. <h3>Conclusions and Relevance</h3> This study found that most women tolerated pregnancy and lactation after SCAD without evidence for increased risk of SCAD recurrence when compared with women with a history of SCAD who did not experience pregnancy. Although this study is reassuring and indicates complex contributors to SCAD recurrence, the results need to be interpreted prudently because of study selection bias and the small total number of women who became pregnant after SCAD. The notable hemodynamic changes that occur with pregnancy and severe presentation of pregnancy-associated SCAD are reasons for concern when considering pregnancy after SCAD.
1165P Subgroup analysis by Ki-67 and primary tumour origins of the randomized, placebo-controlled phase III study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumours (SANET-ep)
Authors: Z. Zhou, J. Xu, L. Shen, J. Li, C. Bai, Y. Chi, Z. Li, N. Xu, R. Jia, E. Li, T. Liu, Y. Bai, Y. Yuan, X. Li, X. Wang, J. Chen, W. Wang, J. Li, J. He, W. Su
Journal: Annals of Oncology (2020)
751P Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy
Authors: A.O. Siefker-Radtke, Y. Loriot, A. Necchi, R.A. Huddart, E.F. Burgess, A. Rezazadeh, A. O'Hagan, P. De Porre, A. Avadhani, M. Monga, Y. Cherkas, C.H. Moy, A. Santiago-Walker
Journal: Annals of Oncology (2020)
Cell-autonomous hepatocyte-specific GP130 signaling is sufficient to trigger a robust innate immune response in mice
Authors: Neele Schumacher, Karsten Yan, Monja Gandraß, Miryam Müller, Christoph Krisp, Robert Häsler, Antonella Carambia, Jerzy-Roch Nofer, Joanna P. Bernardes, Mouhamad Khouja, Ilka Thomsen, Karel Chalupsky, Julia Bolik, Christoph Hölscher, Thomas Wunderlich, Johannes Herkel, Philip Rosenstiel, Christoph Schramm, Hartmut Schlüter, Thomas Renné, Hans-Willi Mittrücker, Stefan Rose-John, Dirk Schmidt-Arras
Journal: Journal of Hepatology (2020)
1876P A combination model of electronic patient-reported outcomes (ePROs) and lab measurements in prediction of immune related adverse events (irAEs) and treatment response of immune checkpoint inhibitor (ICI) therapies
Authors: S.M.E. Iivanainen, J. Ekstrom, V. Kataja, H. Virtanen, J. Koivunen
Journal: Annals of Oncology (2020)
639P 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide
Authors: J. Carles, T. Alonso, B. Mellado Gonzalez, M.J. Mendez Vidal, S. Vazquez Estevez, A. González del Alba, J.M. Piulats, P. Borrega García, E. Gallardo, R. Morales Barrera, P. Paredes, O. Reig, C. Garcías de España, R. Collado, T. Bonfill, C. Suarez, A. Malfettone, J. Garde
Journal: Annals of Oncology (2020)
534MO First in human study of ONO-4578, a PGE2-receptor EP4 antagonist, in monotherapy and combination with PD-1 checkpoint inhibitor nivolumab in patients with advanced or metastatic solid tumours
Authors: N. Yamamoto, T. Koyama, M. Nishino, S. Iwasa, S. Kondo, K. Sudo, K. Yonemori, T. Yoshida, K. Tamura, T. Ozaki, M. Kondo, T. Shimizu
Journal: Annals of Oncology (2020)
1725P Development and validation of telematic follow-up for cancer patients during the COVID-19 outbreak
Authors: A. Pastorino, M.E. Negru, A. Vigani, F. Vaira, A. Tognoni, A. Ferrari, I. Ricci, M. Rondini, F. Olcese, A. Milano, F. Cozzani, C. Aschele
Journal: Annals of Oncology (2020)
701O Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing
Authors: Z.B. Zengin, C. Weipert, J. Hsu, N. Salgia, J. Saam, T.K. Choueiri, N. Agarwal, S. Pal
Journal: Annals of Oncology (2020)
888MO Effectiveness of brentuximab vedotin in relapsed/refractory classic Hodgkin lymphoma: A systematic review and meta-analysis
Authors: B. von Tresckow, A. Bergamasco, F. Trinchese, F. Gavini, N. Bent-Ennakhil, A. Zomas, G. Castillon, T. Arredondo-Bisono, T. Cristarella, Y. Moride, W.J. Plattel
Journal: Annals of Oncology (2020)
1673MO The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management
Authors: A. Lièvre, A. Turpin, I.L. Ray-Coquard, K. Le Malicot, J. Thariat, G. Ahle, R. Mathieu, V. Sebbagh, D. Debieuvre, A. Canellas, M-L. Garcia-Larnicol, R. Colle, A-C. Hardy-Bessard, L. Mansi, J. Bourhis, P. Gorphe, R. Ursu, A. IDBAIH Ahmed, G. Zalcman, O. Bouche
Journal: Annals of Oncology (2020)
454P Comparative study of metronomic capecitabine and oxaliplatin versus classic XELOX in Egyptian patients with metastatic colorectal cancer
Authors: R.Y. Abu El Ela, M.M. El-Serafy, M.Y. Ismail, S.A.S. Shouman, M.M. Omran, R. Allam
Journal: Annals of Oncology (2020)
Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis
Authors: Peter G. Miller, Adam S. Sperling, Christopher J. Gibson, Kaushik Viswanathan, Cecilia Castellano, Marie McConkey, John Ceremsak, Martin S. Taylor, Sebastian Birndt, Florian Perner, Jon Arnason, Mridul Agrawal, Alison M. Schram, Sarah Nikiforow, German Pihan, Robert P. Hasserjian, Jon C. Aster, Paul La Rosée, Elizabeth A. Morgan, Nancy Berliner, Benjamin L. Ebert
Journal: Blood (2020)
1174P RESUNET (GETNE-2016-01): A phase II study to evaluate the efficacy and safety of the rechallenge with sunitinib in G1/G2 pancreatic neuroendocrine tumours (pNET). A Spanish Task Force Group in neuroendocrine and endocrine tumours (GETNE) study
Authors: E. Grande, P. Espinosa-Olarte, R. Serrano, P. Jimenez, T. Alonso, M. Benavent, J. Capdevila Castillón, A. Lacasta, R. Yaya Tur, A. Carmona, I. Gallegos, R.M. Rodríguez, A.O. Castillo Trujillo, J. Molina Cerrillo, J. Hernando, A. Bujedo Martinez, R. Garcia-Carbonero
Journal: Annals of Oncology (2020)
1808TiP Atezolizumab (ATZ) in combination with carboplatin (Cb) and etoposide (Eto) in the treatment of patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC): A multicenter, phase IIIb, single arm, safety study (MAURIS trial)
Authors: G. Martini, E. Bria, C. Gridelli, M.C. Garassino, A. Ardizzoni, F. De Marinis
Journal: Annals of Oncology (2020)
673P Assessing bone health and osteoporotic risk in patients requiring anti androgen therapy for prostate cancer
Authors: N. Hannaway, X. Jiang, T. Aspray, A. Burns, J. Ferguson, I.D. Pedley, J. Frew, A. Azzabi, R. Pearson, R. Chandler, A. Hughes, H. Showler, A. Bennett, R. McMenemin
Journal: Annals of Oncology (2020)
305P Patterns of acquired mutations in estrogen receptor-positive metastatic breast cancer (MBC) patients identified by comprehensive genomic profiling (CGP)
Authors: K. McGregor, J.S. Ross, N.A. Danziger, E.S. Sokol, J. Venstrom, J.H. Chung, J. Lee, B. Alexander, A.B. Schrock, H. Tukachinsky
Journal: Annals of Oncology (2020)
807O Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label, randomized trial in Japan (NINJA trial)
Authors: K. Omatsu, J. Hamanishi, N. Katsumata, S. Nishio, K. Sawada, S. Takeuchi, D. Aoki, K. Fujiwara, T. Sugiyama, I. Konishi
Journal: Annals of Oncology (2020)
512P External validity of the ARCAD nomogram in a real-life population of older patients with unresectable advanced colorectal cancer
Authors: O. de Rycke, C. Tournigand, A. Pujals, A. Rouquette, H. Blons, M. Laurent, G. Orvoen, P. Boudou Rouquette, J. Poisson, E. Paillaud, F. Canouï-Poitrine, E. Kempf
Journal: Annals of Oncology (2020)
Ambulatory Health Care Service Use and Costs Among Commercially Insured US Adults With Congenital Heart Disease
Authors: Anushree Agarwal, Eric Vittinghoff, Janet J. Myers, R. Adams Dudley, Abigail Khan, Anitha John, Gregory M. Marcus
Journal: JAMA Network Open (2020)

ResultsThe mean (SD) age of 33 892 patients included in the study cohort was 35.2 (14.2) years, and 48.8% were women.Of 16 946 patients, 5168 (30.5%) had complex CHD, 5719 (33.8%) had moderately complex CHD, and 6059 (35.7%) had simple CHD.Compared with individuals without CHD, those with CHD had more comorbidities, more health care visits, and higher expenditures (Table ).After multivariate adjustments, ambulatory costs remained significantly higher for all types of adults with CHD than for those without it (Figure).Among patients with CHD, after multivariate adjustments, factors independently associated with ambulatory costs were 10-year increase in age (cost ratio, 1.17; 95% CI, 1.13-1.21),female sex (cost ratio, 1.14; 95% CI, 1.05-1.23),primary beneficiary (cost ratio, 0.88; 95% CI, 0.81-0.96),complex CHD (cost ratio, 1.43; 95% CI, 1.29-1.59),cardiac comorbidities (cost ratio, 2.17; 95% CI, 1.90-2.46),and noncardiac comorbidities (cost ratio, 1.92; 95% CI, 1.75-2.10)(P < .005for all).
A novel through-the-scope twin clip traction-assisted endoscopic submucosal dissection in an in vitro pig stomach model
Authors: Qiang Zhang
Journal: Endoscopy (2020)

A novel through-the-scope twin clip (TTS-TC) was developed for the closure of large gastrointestinal tract wounds [1] [2]. In the current study, we initially explored the application of TTS-TC traction-assisted endoscopic submucosal dissection (ESD) in an in vitro pig stomach model.
Letter by Wang et al Regarding Article, “White Blood Cells and Blood Pressure: A Mendelian Randomization Study”
Authors: Daxin Wang, Tian Chen, Xinquan Yang
Journal: Circulation (2020)

We read with interest the article titled "White Blood Cells and Blood Pressure: A Mendelian Randomization Study," 1 demonstrating a concordant, positive, and potentially causal relationship of elevated lymphocyte count with higher blood pressure.The adaptive immune response appears to play a key role in blood pressure elevation and end-organ damage.Pollow et al 2 found that deficiency of Rag1 in female mice lacking B and T lymphocytes limited the prohypertensive effects of T lymphocytes from males in angiotensin II-induced hypertension, and this protection might involve sex differences in central or renal T lymphocyte infiltration.It should be noted that although they did not detect greater T cell infiltration in male and female mice after angiotensin II infusion, angiotensin II treatment could increase the number of activated T cells and was associated with significantly increased vascular and renal infiltration of CD4 + and CD8 + T cells in male experimental animals. 3Tipton and Sullivan 3 also found that removing sex hormones by gonadectomy resulted in significant increases in helper T 17 cells and significant decreases in T regulatory lymphocytes in both male and female subjects, suggesting that sex hormones cannot account for all of these observed sex differences in the T cell profile in spontaneously hypertensive rats.Interestingly, under baseline conditions, male spontaneously hypertensive rats had significantly more helper T 17 cells in their kidneys than female rats, whereas which had more T regulatory lymphocytes. 4Sex differences in T cells are also observed in humans, with the proportion of circulating CD4 + T cells producing more interferon γ being greater in women than in men.CD4 + T cells from men produce more interleukin 17, highlighting the sex differences in T cell subpopulations. 4Because these T lymphocyte subsets and cytokines potentially have opposing effects on blood pressure regulation and polarized T cells possess considerable plasticity to change their phenotype and cytokine secretion depending on the environment where the cells live, 5 we speculate that in females, the increase in blood pressure is more dependent on a defect in the ability to suppress proinflammatory T cell infiltration into target organs or functional abnormalities of T regulatory lymphocytes, and we wonder whether the sex of the subject being studied could be considered in the authors' extended work for providing a novel relationship between sex, immune cells, tissue infiltration, and blood pressure.Future lying in the identification of subsets of different cellular types with different host hormonal milieus or sex chromosome complements may be critical to understanding the role of immune cells in blood pressure control, which allows the development of immune-based therapies in both sexes.
LBA60 ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
Authors: M.A. Socinski, R. Cornelissen, M.C. Garassino, J. Clarke, N. Tchekmedyian, J. Molina, J.W. Goldman, G. Bhat, F. Lebel, X. Le
Journal: Annals of Oncology (2020)